Britain and America have signed a key commercial pact that will keep zero duties on UK drug products entering the US market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to boost spending on medicines through the public health system. This pledge ensures that tariffs on these key exports will stay at nothing for a period of the next three years.
This deal is in response to earlier warnings to hike import taxes on patented drug imports, with figures mentioned up to one hundred percent.
"This arrangement with the UK bolsters the global environment for cutting-edge drugs and brings long-overdue equity to American-British pharmaceutical trade," an announcement said.
Trade Impact
Medicines constitute one of the Britain's largest export categories to the America, which is clearly the largest destination for large UK drugmakers.
Statistics indicate that in the 12 months leading up to the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value represented nearly one-fifth of all goods exports in that span.
"This agreement secures work, increases funding and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement involves several key changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Previously, refunds topped 20%.
Industry Background
The deal follows a protracted row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
These tensions were exacerbated by assertions that American consumers were paying several times more for the identical medicines than people in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial investments have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the past decade.
